Daily Archives: September 30, 2019, 8:43 am

Mylan to Pay $30 Million for Disclosure and Accounting Failure Relating to EpiPen

According to the SEC’s complaint, Mylan classified EpiPen as a “generic” drug under the Medicaid Drug Rebate Program, which resulted in Mylan paying much lower rebates to the government than if EpiPen had been classified as a “branded” drug. The complaint alleges that in October 2014, the Centers for Medicare and Medicaid Services (CMS) informed Mylan that EpiPen was misclassified as a generic…

Read More